GRAIL Inc. (NASDAQ: GRAL) Stock Competitors & Peer Comparison
See GRAL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GRAL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GRAL | $121.44 | +1.94% | 5.4B | -12.45 | -$9.75 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.66% |
| TMO | $694.76 | +2.63% | 257.5B | 30.00 | $23.16 | +0.27% |
| DHR | $230.25 | +1.73% | 161.9B | 28.86 | $7.98 | +0.66% |
| IDXX | $676.04 | +0.79% | 53.3B | 47.54 | $14.22 | N/A |
| A | $174.76 | +1.73% | 49.3B | 30.08 | $5.81 | +0.59% |
| WAT | $457.60 | +1.00% | 44.9B | 33.45 | $13.68 | N/A |
| IQV | $271.83 | +2.62% | 44.8B | 22.40 | $12.13 | N/A |
| NTRA | $310.67 | -14.59% | 44.7B | -235.14 | -$1.32 | N/A |
| MTD | $1,722.15 | +2.57% | 34.5B | 39.56 | $43.51 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
GRAL vs DHR-PB Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, GRAL's ROE is -0.16%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, GRAL is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
GRAL vs TMO Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, TMO has a market cap of 257.5B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while TMO trades at $694.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas TMO's P/E ratio is 30.00. In terms of profitability, GRAL's ROE is -0.16%, compared to TMO's ROE of +0.13%. Regarding short-term risk, GRAL is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
GRAL vs DHR Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, DHR has a market cap of 161.9B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while DHR trades at $230.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas DHR's P/E ratio is 28.86. In terms of profitability, GRAL's ROE is -0.16%, compared to DHR's ROE of +0.08%. Regarding short-term risk, GRAL is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check DHR's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
GRAL vs IDXX Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, IDXX has a market cap of 53.3B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while IDXX trades at $676.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas IDXX's P/E ratio is 47.54. In terms of profitability, GRAL's ROE is -0.16%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, GRAL is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check IDXX's competition here
Agilent Technologies, Inc. (NYSE: A)
GRAL vs A Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, A has a market cap of 49.3B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while A trades at $174.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas A's P/E ratio is 30.08. In terms of profitability, GRAL's ROE is -0.16%, compared to A's ROE of +0.20%. Regarding short-term risk, GRAL is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check A's competition here
Waters Corporation (NYSE: WAT)
GRAL vs WAT Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, WAT has a market cap of 44.9B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while WAT trades at $457.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas WAT's P/E ratio is 33.45. In terms of profitability, GRAL's ROE is -0.16%, compared to WAT's ROE of +0.01%. Regarding short-term risk, GRAL is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check WAT's competition here
IQVIA Holdings Inc. (NYSE: IQV)
GRAL vs IQV Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, IQV has a market cap of 44.8B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while IQV trades at $271.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas IQV's P/E ratio is 22.40. In terms of profitability, GRAL's ROE is -0.16%, compared to IQV's ROE of +0.22%. Regarding short-term risk, GRAL is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check IQV's competition here
Natera, Inc. (NASDAQ: NTRA)
GRAL vs NTRA Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, NTRA has a market cap of 44.7B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while NTRA trades at $310.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas NTRA's P/E ratio is -235.14. In terms of profitability, GRAL's ROE is -0.16%, compared to NTRA's ROE of -0.09%. Regarding short-term risk, GRAL is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check NTRA's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
GRAL vs MTD Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, MTD has a market cap of 34.5B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while MTD trades at $1,722.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas MTD's P/E ratio is 39.56. In terms of profitability, GRAL's ROE is -0.16%, compared to MTD's ROE of +149.66%. Regarding short-term risk, GRAL is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check MTD's competition here
Illumina, Inc. (NASDAQ: ILMN)
GRAL vs ILMN Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, ILMN has a market cap of 32.2B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while ILMN trades at $213.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas ILMN's P/E ratio is 42.36. In terms of profitability, GRAL's ROE is -0.16%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, GRAL is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check ILMN's competition here
Labcorp Holdings Inc. (NYSE: LH)
GRAL vs LH Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, LH has a market cap of 29.8B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while LH trades at $366.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas LH's P/E ratio is 21.76. In terms of profitability, GRAL's ROE is -0.16%, compared to LH's ROE of +0.12%. Regarding short-term risk, GRAL is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
GRAL vs DGX Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, DGX has a market cap of 28.2B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while DGX trades at $255.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas DGX's P/E ratio is 25.22. In terms of profitability, GRAL's ROE is -0.16%, compared to DGX's ROE of +0.15%. Regarding short-term risk, GRAL is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
GRAL vs GH Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, GH has a market cap of 20.3B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while GH trades at $150.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas GH's P/E ratio is -43.33. In terms of profitability, GRAL's ROE is -0.16%, compared to GH's ROE of +2.49%. Regarding short-term risk, GRAL is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
GRAL vs EXAS Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas EXAS's P/E ratio is -95.37. In terms of profitability, GRAL's ROE is -0.16%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, GRAL is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
GRAL vs MEDP Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, MEDP has a market cap of 18.3B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while MEDP trades at $653.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas MEDP's P/E ratio is 36.22. In terms of profitability, GRAL's ROE is -0.16%, compared to MEDP's ROE of +1.00%. Regarding short-term risk, GRAL is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
GRAL vs RVTY Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, RVTY has a market cap of 17.3B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while RVTY trades at $155.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas RVTY's P/E ratio is 29.01. In terms of profitability, GRAL's ROE is -0.16%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, GRAL is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
GRAL vs ILMNV Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas ILMNV's P/E ratio is N/A. In terms of profitability, GRAL's ROE is -0.16%, compared to ILMNV's ROE of N/A. Regarding short-term risk, GRAL is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check ILMNV's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
GRAL vs CRL Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, CRL has a market cap of 16.2B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while CRL trades at $337.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas CRL's P/E ratio is 34.09. In terms of profitability, GRAL's ROE is -0.16%, compared to CRL's ROE of +0.01%. Regarding short-term risk, GRAL is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
GRAL vs ICLR Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, ICLR has a market cap of 15.3B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while ICLR trades at $204.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas ICLR's P/E ratio is 16.71. In terms of profitability, GRAL's ROE is -0.16%, compared to ICLR's ROE of +0.05%. Regarding short-term risk, GRAL is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check ICLR's competition here
PerkinElmer, Inc. (NYSE: PKI)
GRAL vs PKI Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas PKI's P/E ratio is 41.45. In terms of profitability, GRAL's ROE is -0.16%, compared to PKI's ROE of +0.04%. Regarding short-term risk, GRAL is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check PKI's competition here
Qiagen N.V. (NYSE: QGEN)
GRAL vs QGEN Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while QGEN trades at $50.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas QGEN's P/E ratio is 20.79. In terms of profitability, GRAL's ROE is -0.16%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, GRAL is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
GRAL vs RDNT Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, RDNT has a market cap of 6B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while RDNT trades at $76.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas RDNT's P/E ratio is 164.87. In terms of profitability, GRAL's ROE is -0.16%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, GRAL is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check RDNT's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
GRAL vs BLLN Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, BLLN has a market cap of 5.4B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while BLLN trades at $113.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas BLLN's P/E ratio is 162.81. In terms of profitability, GRAL's ROE is -0.16%, compared to BLLN's ROE of +0.09%. Regarding short-term risk, GRAL is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
GRAL vs SHC Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, SHC has a market cap of 4.6B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while SHC trades at $16.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas SHC's P/E ratio is 16.68. In terms of profitability, GRAL's ROE is -0.16%, compared to SHC's ROE of +0.26%. Regarding short-term risk, GRAL is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
GRAL vs SYNH Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas SYNH's P/E ratio is 61.40. In terms of profitability, GRAL's ROE is -0.16%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, GRAL is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check SYNH's competition here
CareDx, Inc (NASDAQ: CDNA)
GRAL vs CDNA Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, CDNA has a market cap of 4.1B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while CDNA trades at $78.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas CDNA's P/E ratio is 93.46. In terms of profitability, GRAL's ROE is -0.16%, compared to CDNA's ROE of +0.34%. Regarding short-term risk, GRAL is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
GRAL vs OLK Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas OLK's P/E ratio is -96.59. In terms of profitability, GRAL's ROE is -0.16%, compared to OLK's ROE of -0.07%. Regarding short-term risk, GRAL is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check OLK's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
GRAL vs NEO Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, NEO has a market cap of 2.2B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while NEO trades at $16.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas NEO's P/E ratio is 129.54. In terms of profitability, GRAL's ROE is -0.16%, compared to NEO's ROE of -0.04%. Regarding short-term risk, GRAL is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check NEO's competition here
Veracyte, Inc. (NASDAQ: VCYT)
GRAL vs VCYT Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, VCYT has a market cap of 1.9B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while VCYT trades at $24.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas VCYT's P/E ratio is 12.07. In terms of profitability, GRAL's ROE is -0.16%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, GRAL is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check VCYT's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
GRAL vs WGS Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, WGS has a market cap of 1.9B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while WGS trades at $62.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas WGS's P/E ratio is 173.25. In terms of profitability, GRAL's ROE is -0.16%, compared to WGS's ROE of -0.39%. Regarding short-term risk, GRAL is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
GRAL vs PSNL Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while PSNL trades at $15.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas PSNL's P/E ratio is -14.48. In terms of profitability, GRAL's ROE is -0.16%, compared to PSNL's ROE of -0.50%. Regarding short-term risk, GRAL is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
GRAL vs OPK Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, OPK has a market cap of 1.3B. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while OPK trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas OPK's P/E ratio is -19.17. In terms of profitability, GRAL's ROE is -0.16%, compared to OPK's ROE of -0.12%. Regarding short-term risk, GRAL is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
GRAL vs CSTL Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, CSTL has a market cap of 993.2M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while CSTL trades at $32.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas CSTL's P/E ratio is -49.26. In terms of profitability, GRAL's ROE is -0.16%, compared to CSTL's ROE of -0.05%. Regarding short-term risk, GRAL is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
GRAL vs FLGT Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, FLGT has a market cap of 654.3M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while FLGT trades at $23.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas FLGT's P/E ratio is 2378.00. In terms of profitability, GRAL's ROE is -0.16%, compared to FLGT's ROE of -0.09%. Regarding short-term risk, GRAL is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
GRAL vs GRALV Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas GRALV's P/E ratio is N/A. In terms of profitability, GRAL's ROE is -0.16%, compared to GRALV's ROE of N/A. Regarding short-term risk, GRAL is more volatile compared to GRALV. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check GRALV's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
GRAL vs MYGN Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, MYGN has a market cap of 564.3M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while MYGN trades at $5.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas MYGN's P/E ratio is -45.38. In terms of profitability, GRAL's ROE is -0.16%, compared to MYGN's ROE of -0.40%. Regarding short-term risk, GRAL is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
GRAL vs CO Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas CO's P/E ratio is 5.06. In terms of profitability, GRAL's ROE is -0.16%, compared to CO's ROE of +0.11%. Regarding short-term risk, GRAL is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
GRAL vs FLDM Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas FLDM's P/E ratio is -4.74. In terms of profitability, GRAL's ROE is -0.16%, compared to FLDM's ROE of +0.26%. Regarding short-term risk, GRAL is more volatile compared to FLDM. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check FLDM's competition here
Exagen Inc. (NASDAQ: XGN)
GRAL vs XGN Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, XGN has a market cap of 140.5M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while XGN trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas XGN's P/E ratio is -7.16. In terms of profitability, GRAL's ROE is -0.16%, compared to XGN's ROE of -1.22%. Regarding short-term risk, GRAL is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check XGN's competition here
Genetron Holdings Limited (NASDAQ: GTH)
GRAL vs GTH Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas GTH's P/E ratio is -1.11. In terms of profitability, GRAL's ROE is -0.16%, compared to GTH's ROE of -1.01%. Regarding short-term risk, GRAL is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
GRAL vs GENE Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas GENE's P/E ratio is -38.25. In terms of profitability, GRAL's ROE is -0.16%, compared to GENE's ROE of -1.85%. Regarding short-term risk, GRAL is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check GENE's competition here
Freenome, Inc. (NASDAQ: FRNM)
GRAL vs FRNM Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, FRNM has a market cap of 83M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while FRNM trades at $10.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas FRNM's P/E ratio is N/A. In terms of profitability, GRAL's ROE is -0.16%, compared to FRNM's ROE of N/A. Regarding short-term risk, GRAL is more volatile compared to FRNM. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check FRNM's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
GRAL vs IMDX Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, IMDX has a market cap of 81.5M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while IMDX trades at $2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas IMDX's P/E ratio is -1.67. In terms of profitability, GRAL's ROE is -0.16%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, GRAL is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check IMDX's competition here
Biodesix, Inc. (NASDAQ: BDSX)
GRAL vs BDSX Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, BDSX has a market cap of 69.8M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while BDSX trades at $8.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas BDSX's P/E ratio is -2.71. In terms of profitability, GRAL's ROE is -0.16%, compared to BDSX's ROE of -4.42%. Regarding short-term risk, GRAL is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check BDSX's competition here
Precipio, Inc. (NASDAQ: PRPO)
GRAL vs PRPO Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, PRPO has a market cap of 33.5M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while PRPO trades at $18.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas PRPO's P/E ratio is -28.78. In terms of profitability, GRAL's ROE is -0.16%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, GRAL is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
GRAL vs AKU Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas AKU's P/E ratio is -0.13. In terms of profitability, GRAL's ROE is -0.16%, compared to AKU's ROE of -5.32%. Regarding short-term risk, GRAL is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check AKU's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
GRAL vs BIAF Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, BIAF has a market cap of 17.3M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while BIAF trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas BIAF's P/E ratio is -0.32. In terms of profitability, GRAL's ROE is -0.16%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, GRAL is more volatile compared to BIAF. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check BIAF's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
GRAL vs CEMI Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas CEMI's P/E ratio is -0.63. In terms of profitability, GRAL's ROE is -0.16%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, GRAL is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
GRAL vs ENZ Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas ENZ's P/E ratio is -2.24. In terms of profitability, GRAL's ROE is -0.16%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, GRAL is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check ENZ's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
GRAL vs QUCY Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, QUCY has a market cap of 16.3M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while QUCY trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas QUCY's P/E ratio is -0.03. In terms of profitability, GRAL's ROE is -0.16%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, GRAL is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check QUCY's competition here
Psychemedics Corporation (NASDAQ: PMD)
GRAL vs PMD Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas PMD's P/E ratio is -5.24. In terms of profitability, GRAL's ROE is -0.16%, compared to PMD's ROE of -0.32%. Regarding short-term risk, GRAL is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
GRAL vs ME Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas ME's P/E ratio is -0.03. In terms of profitability, GRAL's ROE is -0.16%, compared to ME's ROE of -3.47%. Regarding short-term risk, GRAL is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check ME's competition here
MDxHealth S.A. (NASDAQ: MDXH)
GRAL vs MDXH Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, MDXH has a market cap of 15.3M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while MDXH trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas MDXH's P/E ratio is -0.22. In terms of profitability, GRAL's ROE is -0.16%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, GRAL is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check MDXH's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
GRAL vs MYNZ Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, GRAL's ROE is -0.16%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, GRAL is more volatile compared to MYNZ. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
GRAL vs BNR Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, BNR has a market cap of 14.5M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while BNR trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas BNR's P/E ratio is -15.79. In terms of profitability, GRAL's ROE is -0.16%, compared to BNR's ROE of -0.13%. Regarding short-term risk, GRAL is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check BNR's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
GRAL vs CHEK Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas CHEK's P/E ratio is -0.43. In terms of profitability, GRAL's ROE is -0.16%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, GRAL is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
GRAL vs CNTG Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas CNTG's P/E ratio is -0.23. In terms of profitability, GRAL's ROE is -0.16%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, GRAL is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check CNTG's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
GRAL vs APDN Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas APDN's P/E ratio is -0.10. In terms of profitability, GRAL's ROE is -0.16%, compared to APDN's ROE of -7.23%. Regarding short-term risk, GRAL is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
GRAL vs NDRA Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, NDRA has a market cap of 7.1M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while NDRA trades at $4.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas NDRA's P/E ratio is -0.70. In terms of profitability, GRAL's ROE is -0.16%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, GRAL is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check NDRA's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
GRAL vs BIAFW Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, BIAFW has a market cap of 7M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas BIAFW's P/E ratio is 0.75. In terms of profitability, GRAL's ROE is -0.16%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, GRAL is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check BIAFW's competition here
Invitae Corporation (NYSE: NVTA)
GRAL vs NVTA Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas NVTA's P/E ratio is -0.00. In terms of profitability, GRAL's ROE is -0.16%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, GRAL is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
GRAL vs LMDXW Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, GRAL's ROE is -0.16%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, GRAL is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
GRAL vs LMDX Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas LMDX's P/E ratio is -0.01. In terms of profitability, GRAL's ROE is -0.16%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, GRAL is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check LMDX's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
GRAL vs ADVB Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, ADVB has a market cap of 3.3M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while ADVB trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas ADVB's P/E ratio is -18.32. In terms of profitability, GRAL's ROE is -0.16%, compared to ADVB's ROE of +1.22%. Regarding short-term risk, GRAL is more volatile compared to ADVB. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check ADVB's competition here
DermTech, Inc. (NASDAQ: DMTK)
GRAL vs DMTK Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas DMTK's P/E ratio is -0.04. In terms of profitability, GRAL's ROE is -0.16%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, GRAL is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
GRAL vs NOTV Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas NOTV's P/E ratio is -0.03. In terms of profitability, GRAL's ROE is -0.16%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, GRAL is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
GRAL vs SQL Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas SQL's P/E ratio is -0.40. In terms of profitability, GRAL's ROE is -0.16%, compared to SQL's ROE of -30.46%. Regarding short-term risk, GRAL is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
GRAL vs AWH Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas AWH's P/E ratio is -0.09. In terms of profitability, GRAL's ROE is -0.16%, compared to AWH's ROE of +1.62%. Regarding short-term risk, GRAL is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check AWH's competition here
iSpecimen Inc. (NASDAQ: ISPC)
GRAL vs ISPC Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, ISPC has a market cap of 2M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while ISPC trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas ISPC's P/E ratio is -0.03. In terms of profitability, GRAL's ROE is -0.16%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, GRAL is more volatile compared to ISPC. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check ISPC's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
GRAL vs HTGM Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas HTGM's P/E ratio is -0.03. In terms of profitability, GRAL's ROE is -0.16%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, GRAL is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
GRAL vs BIOC Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas BIOC's P/E ratio is -0.01. In terms of profitability, GRAL's ROE is -0.16%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, GRAL is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
GRAL vs SQLLW Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, GRAL's ROE is -0.16%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, GRAL is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
GRAL vs WGSWW Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, GRAL's ROE is -0.16%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, GRAL is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check WGSWW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
GRAL vs OCDX Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas OCDX's P/E ratio is -42.28. In terms of profitability, GRAL's ROE is -0.16%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, GRAL is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check OCDX's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
GRAL vs PRXL Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas PRXL's P/E ratio is 42.97. In terms of profitability, GRAL's ROE is -0.16%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, GRAL is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check PRXL's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
GRAL vs NDRAW Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas NDRAW's P/E ratio is N/A. In terms of profitability, GRAL's ROE is -0.16%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, GRAL is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check NDRAW's competition here
Danaher Corporation (NYSE: DHR-PA)
GRAL vs DHR-PA Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, GRAL's ROE is -0.16%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, GRAL is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for GRAL.Check DHR-PA's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
GRAL vs CHEKZ Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, GRAL's ROE is -0.16%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, GRAL is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check CHEKZ's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
GRAL vs MEUSW Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas MEUSW's P/E ratio is N/A. In terms of profitability, GRAL's ROE is -0.16%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, GRAL is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check MEUSW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
GRAL vs BNGOW Comparison November 2026
GRAIL Inc. (NASDAQ: GRAL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAL stands at 5.4B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, GRAL is priced at $121.44 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAL currently has a P/E ratio of -12.45, whereas BNGOW's P/E ratio is N/A. In terms of profitability, GRAL's ROE is -0.16%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, GRAL is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for GRAL.Check BNGOW's competition here